InVivo Therapeutics Receives Clinical Trial Application Approval from UK’s Medicines Healthcare Products Regulatory … – Business Wire (press…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV)today announced that the Medicines Healthcare Products Regulatory Agency (MHRA) has approved the companys Clinical Trial Authorization Application to commence clinical studies in the United Kingdom (UK). The approval will allow the company to enroll patients from the UK into the ongoing INSPIRE study once InVivo receives a favorable opinion from a Research Ethics Committee (REC), Health Regulatory Approval (HRA), and a site is open for enrollment. InVivo currently is in late-stage conversation with various clinical sites, and its first UK site opening should occur in the coming weeks.

We are very pleased to be expanding the INSPIRE study beyond the U.S. and Canada to Europe, Mark Perrin, InVivos CEO and Chairman, said. The benefits of working within the MHRA regulatory construct are readily apparent: only one REC needs to review the study for the whole of UK, compared with individual IRB approvals in the US; site specific assessments are fairly quick; and patients are treated at designated centers of excellence. We look forward to announcing our first UK site.

About The INSPIRE Study

The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury, is designed to demonstrate the safety and probable benefit of theNeuro-Spinal Scaffold for the treatment of complete T2-T12/L1 spinal cord injury in support of a Humanitarian Device Exemption (HDE) application for approval. For more information, refer to https://clinicaltrials.gov/ct2/show/study/NCT02138110.

About the Neuro-Spinal Scaffold Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Childrens Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the companys investigational Neuro-Spinal Scaffold received the 2015 Beckers Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit http://www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "believe," "anticipate," "intend," "estimate," "will," "may," "should," "expect," designed to, potentially, and similar expressions, and include statements regarding the safety and effectiveness of the Neuro-Spinal Scaffold, the expected timing of full enrollment in the study, the likelihood of obtaining REC and HRA approval, the ability of the company to open a site or enroll patients in the United Kingdom, and the timing of the submission of the Humanitarian Device Exemption (HDE). Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companys ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board, REC and HRA processes; the impact of achieving the OPC on the FDA approval process; the companys ability to commercialize its products; the companys ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the companys products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the companys business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the companys Annual Report on Form 10-K for the year ended December 31, 2016, and its other filings with the SEC, including the companys Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

Read the rest here:
InVivo Therapeutics Receives Clinical Trial Application Approval from UK's Medicines Healthcare Products Regulatory ... - Business Wire (press...